Claudia A Daubenberger

Oct 24, 2024 | nature.com | Robert Mitchell |Akshayata Naidu |Pedro Aide |Ruth Aguilar |Claudia A Daubenberger |Carlota Dobaño | +1 more

AbstractRTS,S/AS01E, the first approved malaria vaccine, demonstrated moderate efficacy during the phase 3 pediatric trial. We previously investigated cell-mediated immune (CMI) responses following the primary 3-dose immunization and now report responses to the booster dose given 18 months later.

Apr 4, 2024 | thelancet.com | Claudia A Daubenberger |Swiss Tropical |Joana Silva

In the first 2 years of implementation of RTS,S, the three primary doses were effectively deployed through national immunisation programmes. There was no evidence of the safety signals that had been observed in the phase 3 trial, and introduction of the vaccine was associated with substantial reductions in hospital admission with severe malaria. Evaluation continues to assess the impact of four doses of RTS,S.